BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34824550)

  • 1. Identification of Three Potential Prognostic Genes in Platinum-Resistant Ovarian Cancer via Integrated Bioinformatics Analysis.
    Zhang X; Wei X; Bai G; Huang X; Hu S; Mao H; Liu P
    Cancer Manag Res; 2021; 13():8629-8646. PubMed ID: 34824550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
    Liu J; Liu Y; Yang C; Liu J; Hao J
    Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer.
    Wang W; Zhang W; Hu Y
    PeerJ; 2021; 9():e12353. PubMed ID: 34820170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
    Li Y; Nie Y; Guo H; Guo H; Ha C; Li Y
    Front Oncol; 2022; 12():847085. PubMed ID: 35372049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
    Yue C; Ma H; Zhou Y
    PeerJ; 2019; 7():e8128. PubMed ID: 31803536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
    Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
    J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UCHL-3 as a potential biomarker of ovarian cancer.
    Yang Q; Peng X; Nian Z; Yuan S; Wang Z; Song Y; Shamsnur R; Wang H; Yi T
    Gynecol Oncol; 2024 Mar; 182():156-167. PubMed ID: 38266402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Prognostic Risk Model Based on Oxidative StressRelated Genes for Platinum-Resistant Ovarian Cancer Patients.
    Su H; Hou Y; Zhu D; Pang R; Tian S; Ding R; Chen Y; Zhang S
    Recent Pat Anticancer Drug Discov; 2024 May; ():. PubMed ID: 38756073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDF1 Promoted Proliferation and Metastasis of Epithelial Ovarian Cancer
    Zhu C; Liu Y; Tong R; Guan J
    Front Genet; 2022; 13():808100. PubMed ID: 35281796
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
    Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
    J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and prognostic value of potential biomarkers for ovarian cancer.
    Li H; Li M; Tang C; Xu L
    Ann Transl Med; 2021 Jun; 9(12):1007. PubMed ID: 34277807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-mRNA risk score system and nomogram constructed for patients with ovarian cancer.
    Wang Q; Lu Z; Ma J; Zhang Q; Wang N; Qian L; Zhang J; Chen C; Lu B
    Oncol Lett; 2019 Aug; 18(2):1235-1245. PubMed ID: 31423184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
    Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.
    Guo W; He X; Ni J; Ma L; Cheng X; Wang C; Chen X; Wang Y
    Front Oncol; 2021; 11():761960. PubMed ID: 34888242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.